Lantern PharmaLTRN
Oncology11 cited findings Ā· profile updated 2026-08-20
2.49 USDnot live ā refreshed daily
About Lantern Pharma
Lantern Pharma (LTRN) is an oncology-focused research site. The company's pipeline includes LP-184 (zirdafulven), which is in a Phase 1b/2 trial with an enrollment of 39 patients. The primary endpoint for this trial is objective response rate by RECIST 1.1.
Another key drug, LP-300 (HARMONICā¢), has shown a median progression-free survival of 8.9 months and 8.4 months in separate findings. LP-300 (HARMONICā¢) also demonstrated a clinical benefit rate of 77% and a tumor reduction of 70%. Additionally, LP-284 has received Orphan Drug Designations in the United States.
Compiled from the cited findings below ā figures are as stated in each company's published technical reports and filings.
Key figures ā cited
| Median progression-free survival | 8.9 months (LP-300 (HARMONICā¢)) | Lantern Pharma Inc. ā SEC 8-K (2026-08-14), p.1 |
| Median progression-free survival | 8.4 months (LP-300 (HARMONICā¢)) | Lantern Pharma Inc. ā SEC 8-K (2026-08-14), p.1 |
| Clinical benefit rate | 77% (LP-300 (HARMONICā¢)) | Lantern Pharma Inc. ā SEC 8-K (2026-08-14), p.1 |
| Tumor reduction | 70% (LP-300 (HARMONICā¢)) | Lantern Pharma Inc. ā SEC 8-K (2026-08-14), p.1 |
| Enrollment | 39 patients (LP-184 (zirdafulven)) | Lantern Pharma Inc. ā SEC 8-K (2026-08-14), p.6 |
| Orphan Drug Designations | received (LP-284) | Lantern Pharma Inc. ā SEC 8-K (2026-08-14), p.7 |
Key projects
- LP-184 (zirdafulven)
LP-184 is in a Phase 1b/2 trial with an enrollment of 39 patients.
- LP-300 (HARMONICā¢)
LP-300 (HARMONICā¢) demonstrated a clinical benefit rate of 77%.
- LP-284 ā United States
LP-284 has received Orphan Drug Designations in the United States.
Every figure cites its source document. Prices refresh daily, not live. Informational only ā not investment advice. Explore the Oncology research library ā